Smith & Nephew SNATS Inc

Paterniano Del Favero
Agosto 7, 2017

The firm now has a GBX 1,160 ($15.30) target price on the stock. SG Americas Securities LLC bought a new position in Smith & Nephew plc during the second quarter valued at about $641,000. Wrapmanager Inc. increased its position in Smith & Nephew plc by 2.1% in the second quarter. RMB Capital Management LLC purchased a new position in shares of Smith & Nephew SNATS during the first quarter valued at approximately $219,000.

Smith & Nephew SNATS (NYSE:SNN) traded down 0.59% during mid-day trading on Tuesday, hitting $35.12. Smith & Nephew SNATS has a 52 week low of $26.97 and a 52 week high of $35.85. The value of the investment in Smith & Nephew SNATS, Inc. went from $815,000 to $859,000 a change of $44,000 for the reporting period. Proficio Capital Partners LLC expanded its holdings by buying 10 shares an increase of 0.5% in the quarter. US Bancorp DE raised its position in Smith & Nephew SNATS by 20.3% in the second quarter. The stock had a trading volume of 140,671 shares. Capstone Asset Management Co. now owns 252,310 shares of the medical equipment provider's stock valued at $7,804,000 after buying an additional 30,160 shares during the period. "(NYSE:SNN) Upgraded to "Buy" at Zacks Investment Research" was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem.

Dalton Greiner Hartman Maher & Co. increased its stake in Smith & Nephew SNATS, Inc.

A number of other research analysts also recently weighed in on SNN.

Smith & Nephew plc (LON:SN) had its target price hoisted by Jefferies Group LLC from GBX 1,350 ($17.81) to GBX 1,515 ($19.98) in a research note issued to investors on Friday, Marketbeat Ratings reports. The company has a market cap of $15.34 billion, a price-to-earnings ratio of 17.84 and a beta of 0.76. The company has a 50-day moving average of $34.83 and a 200 day moving average of $32.75. HSBC Holdings plc reaffirmed a hold rating and set a GBX 1,320 ($17.41) price objective on shares of Smith & Nephew plc in a research note on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company's stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and global copyright & trademark laws. The legal version of this story can be viewed at https://www.thestockobserver.com/2017/08/07/smith-nephew-plc-lonsn-stock-rating-reaffirmed-by-credit-suisse-group-updated-updated.html. The company now has an average rating of "Hold" and an average price target of $38.00.

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies, Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE